Sheng-Yin Chen

Dr. Sheng-Yin Chen

Chang Gung University, Taoyuan City, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Juliane LibertoJuliane Liberto
Juliane Liberto
SCSheng-Yin Chen
Sheng-Yin Chen
ISIe-Ming Shih
Ie-Ming Shih
TWTza-Huei Wang
Tza-Huei Wang
TWTian-Li Wang
Tian-Li Wang
Thomas R. Pisanic IIThomas R. Pisanic II
Thomas R. Pisanic II
With a 5-year survival rate of less than 50%, ovarian high-grade serous carcinoma (HGSC) is one of the most highly aggressive gynecological malignancies affecting women today. The high mortality rate of HGSC is largely attributable to delays in diagnosis, as most patients remain undiagnosed until the late stages of -disease. There are currently no recommended screening tests for ovarian cancer and there thus remains an urgent need for new diagnostic methods, particularly those that can detect the disease at early stages when clinical intervention remains effective. While diagnostics for ovarian cancer share many of the same technical hurdles as for other cancer types, the low prevalence of the disease in the general population, coupled with a notable lack of sensitive and specific biomarkers, have made the development of a clinically useful screening strategy particularly challenging. Here, we present a detailed review of the overall landscape of ovarian cancer diagnostics, with emphasis on emerging methods that employ novel protein, genetic, epigenetic and imaging-based biomarkers and/or advanced diagnostic technologies for the noninvasive detection of HGSC, particularly in women at high risk due to germline mutations such as BRCA1/2. Lastly, we discuss the translational potential of these approaches for achieving a clinically implementable solution for screening and diagnostics of early-stage ovarian cancer as a means of ultimately improving patient outcomes in both the general and high-risk populations.

13 December 2022 in eClinicalMedicine
Verified
Journal Article
Open access
CSChing-Chun Su
Ching-Chun Su
JCJui-Yi Chen
Jui-Yi Chen
SCSheng-Yin Chen
Sheng-Yin Chen
CSChih-Chung Shiao
Chih-Chung Shiao
JNJavier A. Neyra
Javier A. Neyra
VWVin-Cent Wu
Vin-Cent Wu
Acute kidney disease (AKD) defines the period after kidney damage and it is a critical period of both repair and fibrotic pathways. However, the outcomes of patients with AKD have not been well-defined. In this meta-analysis, PubMed, Embase, Cochrane and China National Knowledge Infrastructure were searched on July 31,2022. We excluded studies including patients undergoing kidney replacement therapy at enrollment. The data was used to conduct a random-effects model for pool outcomes between patients with AKD and non-AKD (NKD). This study is registered with PROSPERO, CRD 42021271773. The search generated 739 studies of which 21 studies were included involving 1,114,012 patients. The incidence rate of community-acquired AKD was 4.60%, 2.11% in hospital-acquired AKD without a prior AKI episode, and 26.11% in hospital-acquired AKD with a prior AKI episode. The all-cause mortality rate was higher in the AKD group (26.54%) than in the NKD group (7.78%) (odds ratio [OR]: 3.62, 95% confidence interval [CI]: 2.64 to 4.95, p < 0.001, I2 = 99.11%). The rate of progression to end-stage kidney disease (ESKD) was higher in the AKD group (1.3%) than in the NKD group (0.14%) (OR: 6.58, p < 0.001, I2 = 94.95%). The incident rate of CKD and progressive CKD was higher in the AKD group (37.2%) than in the NKD group (7.45%) (OR:4.22, p < 0.001, I2 = 96.67%). Compared to the NKD group, patients with AKD without prior AKI had a higher mortality rate (OR: 3.00, p < 0.001, I2 = 99.31%) and new-onset ESKD (OR:4.96, 95% CI, p = 0.002, I2 = 97.37%). AKD is common in community and hospitalized patients who suffer from AKI and also occurs in patients without prior AKI. The patients with AKD, also in those without prior AKI had a higher risk of mortality, and new-onset ESKD than the NKD group. This study was supported by 10.13039/501100004663 Ministry of Science and Technology (MOST) of the Republic of China (Taiwan) [grant number, MOST 107-2314-B-002-026-MY3, 108-2314-B-002-058, 110-2314-B-002-241, 110-2314-B-002-239], National Science and Technology Council (NSTC) [grant number, NSTC 109-2314-B-002-174-MY3, 110-2314-B-002-124-MY3, 111-2314-B-002-046, 111-2314-B-002-058], 10.13039/501100004737 National Health Research Institutes [PH-102-SP-09], 10.13039/501100005762 National Taiwan University Hospital [109-S4634, PC-1246, PC-1309, VN109-09, UN109-041, UN110-030, 111-FTN0011] Grant MOHW110-TDU-B-212-124005, Mrs. 10.13039/501100009048 Hsiu-Chin Lee Kidney Research Fund and Chi-mei medical center CMFHR11136. JAN is supported, in part, by grants from the 10.13039/100000062 National Institute of Health, NIDDK (R01 DK128208 and P30 DK079337) and 10.13039/100000050 NHLBI (R01 HL148448-01).

22 November 2022 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
SCSheng-Yin Chen
Sheng-Yin Chen
JCJui-Yi Chen
Jui-Yi Chen
WHWei-Chieh Huang
Wei-Chieh Huang
TPTroy Hai Kiat Puar
Troy Hai Kiat Puar
PKPeng Chin Kek
Peng Chin Kek
TGTAIPAI Study Group
TAIPAI Study Group
Background: In patients with primary aldosteronism (PA), long-term cardiovascular and mortality outcomes after adrenalectomy vs mineralocorticoid receptor antagonist (MRA) have not been compared yet. We aim to compare the clinical outcomes of these patients after treatment. Design and Methods: A systematic review and meta-analysis was conducted by searching PubMed, Cochrane library, and Embase from no start date restriction to 18 December 2021. Our composite primary outcomes were long-term all-cause mortality and/or major adverse cardiovascular events (MACE), including coronary artery disease (CAD), stroke, arrhythmia, and congestive heart failure. We adopted the random-effects model and performed subgroup analyses, meta-regression, and trial sequential analysis (TSA). Results: A total of 9 studies with 8473 adult patients with PA (≥18 years) were enrolled. A lower incidence of composite primary outcomes was observed in the adrenalectomy group (odds ratio (OR): 0.46 (95% CI: 0.38–0.56), P < 0.001). We found a lower incidence of all-cause mortality (OR: 0.33 (95% CI: 0.15–0.73), P = 0.006) and MACE (OR: 0.55, (95% CI: 0.40–0.74), P = 0.0001) in the adrenalectomy group. The incidence of CAD (OR: 0.33 (95% CI: 0.15–0.75), P = 0.008), arrhythmias (OR: 0.46 (95% CI: 0.27–0.81), P = 0.007), and congestive heart failure (OR: 0.52 (95% CI: 0.33–0.81), P = 0.004) was also lower in adrenalectomy group. The metaregression showed patient's age may attenuate the benefits of adrenalectomy on composite primary outcomes (coefficient: 1.084 (95% CI: 1.005–1.169), P = 0.036). TSA demonstrated that the accrued sample size and effect size were sufficiently large to draw a solid conclusion, and the advantage of adrenalectomy over MRA was constant with the chronological sequence. Conclusions: In conclusion, adrenalectomy could be preferred over MRA for patients with PA in reducing the risk of all-cause mortality and/or MACE and should be considered as the treatment of choice. That patients with PA could get less benefit from adrenalectomy as they age warrants further investigation.

23 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSheng-Yin Chen
Sheng-Yin Chen
HKHanseul Kim
Hanseul Kim
ENEtienne Nzabarushimana
Etienne Nzabarushimana
JSJiaxian Shen
Jiaxian Shen
KWKatherine Williams
Katherine Williams
HKHamed Khalili
Hamed Khalili
Microscopic colitis (MC) is a chronic inflammatory disease of the large intestine that primarily affects older adults and presents with chronic diarrhea. The etiology is unknown and there are currently no FDA approved medications or biomarkers for treatment or monitoring of the disease. Emerging evidence have implicated the gut microbiome and metabolome disturbances in MC pathogenesis. We conduct a comprehensive analysis of gut microbial and metabolic changes in a cohort of 683 participants, including 131 patients with active MC, 159 with chronic diarrhea, and 393 age- and sex-matched controls without diarrhea. Stool microbiome and metabolome are profiled using whole-genome shotgun metagenomic sequencing and ultra-high performance liquid chromatography–mass spectrometry, respectively. Compared to controls, eight microbial species including pro-inflammatory oral-typical Veillonella dispar and Haemophilus parainfluenzae, and 11 species, including anti-inflammatory Blautia glucerasea and Bacteroides stercoris are enriched and depleted in MC, respectively. Pro-inflammatory metabolites, including lactosylceramides, ceramides, lysophospholipids, and lysoplasmalogens, are enriched in active MC. Multi-omics analyses reveal robust associations between microbial species, metabolic pathways, and metabolites, suggesting concordant disruptions in MC. Here, we show distinct shifts in gut microbiome and metabolome in MC that can inform the development of non-invasive biomarkers and novel therapeutics.

21 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
JDJingwen Janice Dong
Jingwen Janice Dong
MGMin Gao
Min Gao
LLLin Li
Lin Li
XPXiaoyu Pan
Xiaoyu Pan
SCSheng-Yin Chen
Sheng-Yin Chen
JZJiali Zheng
Jiali Zheng
Chronic inflammation plays a central role in the progression from esophageal precancerous lesions (EPLs) to esophageal squamous-cell cancer (ESCC). However, few studies have investigated the relationship between the overall inflammatory potential of diets and EPLs and ESCC. We aimed to study the association between the Dietary Inflammatory Index (DII) and EPLs and ESCC. As part of the National Cohort of Esophageal Cancer (NCEC) in China, 3967 residents (1993 men and 1974 women) aged from 40 to 69 years living in Yanting County received free gastroscopy screenings from 2017 to 2019. Dietary intake during the past year was assessed at enrollment of the cohort before screening and DII scores were calculated based on 28 food parameters. EPLs (classified into mild, moderate, and severe dysplasia) and ESCC were histologically confirmed by biopsy. Multivariable logistic regression was used to examine the associations of DII scores with EPLs and ESCC. A total of 312 participants were diagnosed with EPLs (226 with mild dysplasia, 40 with moderate dysplasia, and 46 with severe dysplasia) and 72 were diagnosed with ESCC. A statistically significant positive association was observed between DII scores and overall EPLs (ORT3 vs. T1 = 1.45, 95%CI = 1.01–2.09); the association was similar but not statistically significant for mild dysplasia (ORone-unit-increment = 1.11, 95%CI = 0.95–1.34) and for moderate and severe dysplasia combined (ORone-unit-increment = 1.15, 95%CI = 0.87–1.51). The association with ESCC was similar in magnitude but not significant, likely due to the small number of cases. In this cross-sectional study of a population in China at high risk of ESCC, DII scores were positively associated with odds of EPLs and ESCC. Consumption of anti-inflammatory foods may be beneficial to prevent EPLs and ESCC.

29 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SCSheng-Yin Chen
Sheng-Yin Chen
HKHanseul Kim
Hanseul Kim
EEEtienne Etienne
Etienne Etienne
JSJiaxian Shen
Jiaxian Shen
KWKatherine Williams
Katherine Williams
HKHamed Khalili
Hamed Khalili
Background: Microscopic colitis (MC) is a common cause of chronic diarrhea, predominantly among older adults. Emerging evidence suggests that perturbations of gut microbiome and metabolome may play an important role in MC pathogenesis. Objective: To comprehensively characterize alterations of the gut microbial and metabolic composition in MC. Design: We established a longitudinal cohort of adult patients with MC and two control groups of individuals – chronic diarrhea controls and age- and sex-matched controls without diarrhea. Using stool samples, gut microbiome was analyzed by whole-genome shotgun metagenomic sequencing, and gut metabolome was profiled by ultra-high performance liquid chromatography–mass spectrometry. Per-feature enrichment analyses of microbial species, metabolic pathways, and metabolites were done using multivariable linear models both cross-sectionally comparing MC to controls and longitudinally according to disease activity. Lastly, we performed multi-omics association analyses to assess the relationship between microbiome and metabolome data. Results: We included 683 participants, 131 with active MC (66 with both active and remission samples), 159 with chronic diarrhea, and 393 age- and sex-matched controls without diarrhea. The stool microbiome in active MC was characterized by a lower alpha diversity as compared to controls and the remission phase of MC. Compared to controls, we identified eight enriched species in MC, most of which were pro-inflammatory oral-typical species, such as Veillonella dispar and Haemophilus parainfluenzae . In contrast, 11 species, including anti-inflammatory microbes such as Blautia glucerasea and Bacteroides stercoris, were depleted in MC. Similarly, pro-inflammatory metabolites, including lactosylceramides, ceramides, lysophospholipids, and lysoplasmalogens were enriched in active MC as compared to controls or MC cases in remission. Multi-omics association analyses revealed strong and concordant links between microbes, their metabolic pathways, and metabolomic profiles, supporting the tight interplay between disturbances in stool microbiome and metabolome in MC. Conclusion: We observed a significant shift in stool microbial and metabolomic composition in MC. Our findings could be used in the future for development of non-invasive biomarkers for diagnosing and monitoring MC and developing novel therapeutics. What is already known on this topic: Microbiome dysbiosis has been proposed to contribute to microscopic colitis (MC) pathogenesis. However, previous studies have been limited by small sample sizes, reliance on 16S rRNA sequencing technique, potential confounding by stool consistency, and lack of functional analyses of microbiome and longitudinal data. Moreover, the metabolomic composition of MC remain largely unknown. What this study adds: In this largest longitudinal MC cohort with two control groups – chronic diarrhea controls and controls without diarrhea, gut microbiome of MC is characterized by a lower alpha diversity, enriched pro-inflammatory oral-typical species and depleted anti-inflammatory beneficial species. Gut metabolome of MC shows significant enrichment of pro-inflammatory metabolites, including lactosylceramides, ceramides, lysophospholipids, and lysoplasmalogens. Multi-omics analyses demonstrate strong and concordant relationships between microbes, metabolic pathways, and metabolomic profiles. How this study might affect research, practice or policy: Our findings could facilitate development of non-invasive biomarkers and novel therapeutics for MC.